200 related articles for article (PubMed ID: 24473125)
1. Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days.
Livermore J; Howard SJ; Sharp AD; Goodwin J; Gregson L; Felton T; Schwartz JA; Walker C; Moser B; Müller W; Harrison TS; Perfect JR; Hope WW
mBio; 2014 Jan; 5(1):e00725-13. PubMed ID: 24473125
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis.
Stott KE; Beardsley J; Whalley S; Kibengo FM; Mai NTH; Tùng NLN; Cuc NTK; Kolamunnage-Dona R; Hope W; Day J
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29735567
[TBL] [Abstract][Full Text] [Related]
3. Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis.
Lestner J; McEntee L; Johnson A; Livermore J; Whalley S; Schwartz J; Perfect JR; Harrison T; Hope W
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320715
[TBL] [Abstract][Full Text] [Related]
4. AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.
Lawrence DS; Youssouf N; Molloy SF; Alanio A; Alufandika M; Boulware DR; Boyer-Chammard T; Chen T; Dromer F; Hlupeni A; Hope W; Hosseinipour MC; Kanyama C; Lortholary O; Loyse A; Meya DB; Mosepele M; Muzoora C; Mwandumba HC; Ndhlovu CE; Niessen L; Schutz C; Stott KE; Wang D; Lalloo DG; Meintjes G; Jaffar S; Harrison TS; Jarvis JN
Trials; 2018 Nov; 19(1):649. PubMed ID: 30470259
[TBL] [Abstract][Full Text] [Related]
5. Differences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin B.
Chang T; Olson JA; Proffitt RT; Adler-Moore JP
Med Mycol; 2010 Mar; 48(2):430-5. PubMed ID: 20141377
[TBL] [Abstract][Full Text] [Related]
6. Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits.
Groll AH; Mickiene D; Petraitis V; Petraitiene R; Alfaro RM; King C; Piscitelli SC; Walsh TJ
Antimicrob Agents Chemother; 2003 Dec; 47(12):3917-25. PubMed ID: 14638502
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.
Hamill RJ; Sobel JD; El-Sadr W; Johnson PC; Graybill JR; Javaly K; Barker DE
Clin Infect Dis; 2010 Jul; 51(2):225-32. PubMed ID: 20536366
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits.
Lee JW; Amantea MA; Francis PA; Navarro EE; Bacher J; Pizzo PA; Walsh TJ
Antimicrob Agents Chemother; 1994 Apr; 38(4):713-8. PubMed ID: 8031034
[TBL] [Abstract][Full Text] [Related]
9. Continuous infusion of amphotericin B deoxycholate in the treatment of cryptococcal meningoencephalitis: analysis of safety and fungicidal activity.
Falci DR; Lunardi LW; Ramos CG; Bay MB; Aquino VR; Goldani LZ
Clin Infect Dis; 2010 Mar; 50(5):e26-9. PubMed ID: 20121575
[TBL] [Abstract][Full Text] [Related]
10. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.
Groll AH; Lyman CA; Petraitis V; Petraitiene R; Armstrong D; Mickiene D; Alfaro RM; Schaufele RL; Sein T; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2006 Oct; 50(10):3418-23. PubMed ID: 17005824
[TBL] [Abstract][Full Text] [Related]
11. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis.
Giamberardino CD; Schell WA; Tenor JL; Toffaletti DL; Palmucci JR; Marius C; Boua JK; Soltow Q; Mansbach R; Moseley MA; Thompson JW; Dubois LG; Hope W; Perfect JR; Shaw KJ
mBio; 2022 Dec; 13(6):e0234722. PubMed ID: 36222509
[TBL] [Abstract][Full Text] [Related]
13. Minimum concentration of Amphotericin B in serum according to the formulation, dose, and daily or prolonged intermittent therapeutic regimen.
Schiave LA; Nascimento E; Gaspar GG; Vilar FC; Martinez EZ; Gaitani CM; Martinez R
Rev Soc Bras Med Trop; 2020; 53():e20180463. PubMed ID: 32049198
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients.
O'Connor L; Livermore J; Sharp AD; Goodwin J; Gregson L; Howard SJ; Felton TW; Schwartz JA; Neely MN; Harrison TS; Perfect JR; Hope WW
J Infect Dis; 2013 Jul; 208(2):351-61. PubMed ID: 23599314
[TBL] [Abstract][Full Text] [Related]
15. Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.
Wiederhold NP; Najvar LK; Bocanegra R; Kirkpatrick WR; Sorrell TC; Patterson TF
Antimicrob Agents Chemother; 2013 Feb; 57(2):745-50. PubMed ID: 23165465
[TBL] [Abstract][Full Text] [Related]
16. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.
Brouwer AE; Rajanuwong A; Chierakul W; Griffin GE; Larsen RA; White NJ; Harrison TS
Lancet; 2004 May; 363(9423):1764-7. PubMed ID: 15172774
[TBL] [Abstract][Full Text] [Related]
17. Management of amphotericin-induced phlebitis among HIV patients with cryptococcal meningitis in a resource-limited setting: a prospective cohort study.
Ahimbisibwe C; Kwizera R; Ndyetukira JF; Kugonza F; Sadiq A; Hullsiek KH; Williams DA; Rhein J; Boulware DR; Meya DB
BMC Infect Dis; 2019 Jun; 19(1):558. PubMed ID: 31242860
[TBL] [Abstract][Full Text] [Related]
18. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.
Leenders AC; Reiss P; Portegies P; Clezy K; Hop WC; Hoy J; Borleffs JC; Allworth T; Kauffmann RH; Jones P; Kroon FP; Verbrugh HA; de Marie S
AIDS; 1997 Oct; 11(12):1463-71. PubMed ID: 9342068
[TBL] [Abstract][Full Text] [Related]
19. Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis.
Bicanic T; Bottomley C; Loyse A; Brouwer AE; Muzoora C; Taseera K; Jackson A; Phulusa J; Hosseinipour MC; van der Horst C; Limmathurotsakul D; White NJ; Wilson D; Wood R; Meintjes G; Harrison TS; Jarvis JN
Antimicrob Agents Chemother; 2015 Dec; 59(12):7224-31. PubMed ID: 26349818
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis.
Joly V; Aubry P; Ndayiragide A; Carrière I; Kawa E; Mlika-Cabanne N; Aboulker JP; Coulaud JP; Larouze B; Yeni P
Clin Infect Dis; 1996 Sep; 23(3):556-62. PubMed ID: 8879780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
